ISRCTN11974092已完成不适用
A phase I/II study of vaccination against minor histocompatibility antigens HA1 or HA2 after allogeneic stem cell transplantation for advanced haematological malignancies
Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)0 个研究点目标入组 25 人开始时间: 2008年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Advanced (high risk) leukaemia, after allogeneic haematopoietic stem cell transplantation (HSCT)
- •2. Disparity in HA1 or HA2 between donor and recipient
- •3. Informed consent
- •4. Aged 18 years or older, either sex
排除标准
- •1. Acute or chronic graft-versus-host disease (GvHD) after allo-HSCT prior to immunisation
- •2. No informed consent
研究者
相似试验
终止
1 期
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic MalignanciesPreleukemiaMyeloproliferative DisordersMyelomaGraft Versus Host DiseaseLymphomaNCT00943293University of Chicago1
进行中（未招募）
不适用
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - NDProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage IEUCTR2009-017798-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsEUCTR2008-001918-25-FRGlaxoSmithKline Biologicals48
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30